PL3870213T3 - Stabilne kompozycje semaglutydu i ich zastosowania - Google Patents

Stabilne kompozycje semaglutydu i ich zastosowania

Info

Publication number
PL3870213T3
PL3870213T3 PL19801228.8T PL19801228T PL3870213T3 PL 3870213 T3 PL3870213 T3 PL 3870213T3 PL 19801228 T PL19801228 T PL 19801228T PL 3870213 T3 PL3870213 T3 PL 3870213T3
Authority
PL
Poland
Prior art keywords
stable
semaglutide compositions
semaglutide
compositions
stable semaglutide
Prior art date
Application number
PL19801228.8T
Other languages
English (en)
Inventor
Dorthe Kot Engelund
Søren Skov JENSEN
Joakim LUNDQVIST
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68503076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3870213(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3870213T3 publication Critical patent/PL3870213T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL19801228.8T 2018-10-26 2019-10-25 Stabilne kompozycje semaglutydu i ich zastosowania PL3870213T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18202801 2018-10-26
EP19158226 2019-02-20
PCT/EP2019/079214 WO2020084126A1 (en) 2018-10-26 2019-10-25 Stable semaglutide compositions and uses thereof

Publications (1)

Publication Number Publication Date
PL3870213T3 true PL3870213T3 (pl) 2023-11-20

Family

ID=68503076

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19801228.8T PL3870213T3 (pl) 2018-10-26 2019-10-25 Stabilne kompozycje semaglutydu i ich zastosowania

Country Status (22)

Country Link
US (2) US20210379159A1 (pl)
EP (1) EP3870213B1 (pl)
JP (1) JP7422754B2 (pl)
KR (2) KR20250024094A (pl)
CN (3) CN120617159A (pl)
AU (1) AU2019363725B2 (pl)
CA (1) CA3116271A1 (pl)
CL (1) CL2021000938A1 (pl)
CO (1) CO2021005915A2 (pl)
ES (1) ES2954584T3 (pl)
HR (1) HRP20230929T1 (pl)
HU (1) HUE062893T2 (pl)
IL (1) IL281938B2 (pl)
MX (1) MX2021004331A (pl)
MY (1) MY206306A (pl)
PE (1) PE20211492A1 (pl)
PH (1) PH12021550705A1 (pl)
PL (1) PL3870213T3 (pl)
RS (1) RS64438B1 (pl)
SA (1) SA521421715B1 (pl)
SG (1) SG11202103137WA (pl)
WO (1) WO2020084126A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
IL281938B2 (en) 2018-10-26 2024-04-01 Novo Nordisk As Stable semaglutide compositions and uses thereof
WO2021105393A1 (en) * 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20230165939A1 (en) * 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
AU2022386489A1 (en) * 2021-11-12 2024-05-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
CN114660214B (zh) * 2022-02-18 2024-04-05 兰州积石药业有限公司 一种司美格鲁肽的液相色谱检测方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK136492D0 (da) * 1992-11-10 1992-11-10 Novo Nordisk As A pharmaceutical formulation
SK279641B6 (sk) 1991-12-20 1999-01-11 Novo Nordisk A/S Stabilizovaný farmaceutický prípravok obsahujúci r
WO1999024015A1 (en) 1997-11-12 1999-05-20 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
WO2006029634A2 (en) * 2004-09-17 2006-03-23 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2820038B1 (en) * 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN103566354B (zh) * 2012-07-25 2017-12-05 江苏豪森药业集团有限公司 含有glp‑1类似物的衍生物或其可药用盐的药物组合物
CN104717972A (zh) * 2012-10-17 2015-06-17 诺和诺德A/S（股份有限公司） 用于口服肽递送的脂肪酸酰化氨基酸
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
JP2014214153A (ja) 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
WO2014202727A1 (en) * 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
EP3226906B1 (en) * 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US12569543B2 (en) * 2016-04-28 2026-03-10 Novo Nordisk A/S Semaglutide in cardiovascular conditions
CN107661288A (zh) * 2016-07-29 2018-02-06 江苏泰康生物医药有限公司 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN108210890A (zh) * 2016-12-09 2018-06-29 江苏泰康生物医药有限公司 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
IL281938B2 (en) 2018-10-26 2024-04-01 Novo Nordisk As Stable semaglutide compositions and uses thereof

Also Published As

Publication number Publication date
EP3870213C0 (en) 2023-06-07
BR112021006598A2 (pt) 2021-07-06
ES2954584T3 (es) 2023-11-23
SA521421715B1 (ar) 2023-12-10
HRP20230929T1 (hr) 2023-11-24
KR20210087465A (ko) 2021-07-12
EP3870213B1 (en) 2023-06-07
CA3116271A1 (en) 2020-04-30
CN120617158A (zh) 2025-09-12
PH12021550705A1 (en) 2021-11-03
IL281938B2 (en) 2024-04-01
IL281938B1 (en) 2023-12-01
CN112912100A (zh) 2021-06-04
CN120617159A (zh) 2025-09-12
MY206306A (en) 2024-12-07
JP2022505290A (ja) 2022-01-14
MX2021004331A (es) 2021-05-27
RS64438B1 (sr) 2023-09-29
AU2019363725B2 (en) 2024-05-02
US20210379159A1 (en) 2021-12-09
HUE062893T2 (hu) 2023-12-28
JP7422754B2 (ja) 2024-01-26
EP3870213A1 (en) 2021-09-01
US20240415934A1 (en) 2024-12-19
WO2020084126A1 (en) 2020-04-30
KR20250024094A (ko) 2025-02-18
PE20211492A1 (es) 2021-08-11
IL281938A (en) 2021-05-31
CO2021005915A2 (es) 2021-08-09
SG11202103137WA (en) 2021-04-29
CL2021000938A1 (es) 2021-09-10
AU2019363725A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
SG11202100071YA (en) Fusosome compositions and uses thereof
SG11202011015QA (en) Fusosome compositions and uses thereof
IL279755A (en) Senolytic preparations and their uses
SG11202103137WA (en) Stable semaglutide compositions and uses thereof
SG11202000940XA (en) Glp-1 compositions and uses thereof
IL271275B1 (en) Preparations containing croons and their uses
IL277663A (en) Arunumab preparations and their uses
GB201812334D0 (en) Compositions and uses thereof
IL277441A (en) Variants of LFA3 and their preparations and uses
GB201821138D0 (en) Compositions and uses thereof
GB201807576D0 (en) Compositions and uses thereof
GB201812952D0 (en) Compositions and uses thereof
HK40050996A (en) Stable semaglutide compositions and uses thereof
GB201821144D0 (en) Compositions and uses thereof
GB201819493D0 (en) Compositions and uses thereof
GB201818495D0 (en) Compositions and uses thereof
GB201818375D0 (en) Compositions and uses thereof
GB201808858D0 (en) Compositions and uses thereof
GB201808907D0 (en) Compositions and uses thereof
GB201808298D0 (en) Compositions and uses thereof
GB201808321D0 (en) Compositions and uses thereof
GB201805322D0 (en) Compositions and uses thereof
GB201805097D0 (en) Compositions and uses thereof
GB201805098D0 (en) Compositions and uses thereof
GB201805093D0 (en) Compositions and uses thereof